Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Lineage Cell Therapeutics Inc.
Headquarters: Carlsbad, CA, United States of America
Website: https://lineagecell.com
Year Founded: 1990
Status: Public
Industry Sector: HealthTechnology
CEO: Brian M. Culley, MBA
Number Of Employees: 77
Enterprise Value: $53,936,983
PE Ratio: -4.12
Exchange/Ticker 1: NYSE-A:LCTX
Exchange/Ticker 2: N/A
Latest Market Cap: $98,741,096
BioCentury | Dec 5, 2024
Product Development
Stem cell therapy companies take different roads to reproducibility
But they agree that creating a reliable product is necessary for scalability
BioCentury | Apr 30, 2024
Management Tracks
Innovent hires Gracell vet Samuel Zhang as CBO
Plus: CEO changes at Lexicon, Avacta and Sphere Fluidics, and updates from Generate, Charm, ViaNautis and more
BioCentury | Feb 10, 2024
Finance
Public equity report: IPOs for Kyverna, Metagenomi; 4D, Sana among follow-ons
Plus PIPEs for Adverum, Autolus, Mineralys, Silence, PepGen, Sensorion, Tenaya, Jasper and others
BioCentury | Nov 2, 2022
Management Tracks
New heads of commercial, legal at ADC
Plus Antares vet Powell lands at Lava, and updates from CymaBay, Lineage, CARsgen and more
BioCentury | Oct 19, 2022
Data Byte
The evolving geographic atrophy pipeline
Roche drops galegenimab and NGM data disappoint, as regulatory milestones approach for Apellis, Iveric
BioCentury | Apr 21, 2022
Management Tracks
Romanelli rejoins Merck to lead Human Health International
Plus: SIB’s Durinx joins VIB, and updates from Orion, American Cancer Society, Ambys and more
BioCentury | Dec 21, 2021
Deals
Lineage deal bolsters Roche’s ophthalmology pipeline as Lucentis biosimilars loom
Deal with Genentech allows Lineage to stick to core areas, cancer, spinal injury
BioCentury | Apr 14, 2021
Management Tracks
CEO succession at Amarin; plus Lilly, IGM, Jounce and more
John Thero will retire as president, CEO and board member at Amarin Corp. plc (NASDAQ:AMRN) on August 1. Thero will be replaced by Karim Mikhail, SVP and head of commercial for Europe at the
BioCentury | Jan 23, 2021
Management Tracks
Yale’s Fuchs joins Genentech, Roche; plus Lineage’s Roberts jumps on Longboard as CFO and Avidity, Xalud, AVM, Novavax
Charles “Charlie” Fuchs is joining Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit as SVP and global head of product development for oncology and
Items per page:
1 - 10 of 19